{
    "nctId": "NCT00111787",
    "briefTitle": "Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer",
    "officialTitle": "A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Percentage of participants with pathologic complete response rate (pCR)",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Tumor accessible for multiple biopsies\n* ECOG (Eastern Cooperative Oncology Group) performance status 0-2\n* Adequate bone marrow\n* Renal and hepatic function\n* LVEF (left ventricular ejection fraction) greater than 0% based on ECHO (echocardiogram) or MUGA (multigated acquisition).\n\nExclusion criteria:\n\n* Females who are pregnant or nursing.\n* Any unstable, pre-existing major medical condition.\n* Received an investigational drug within the past 4 weeks.\n* Had major surgery in the past 2 weeks.\n* Currently receiving amiodarone or has received amiodarone in the past 6 months.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}